Xbrane Biopharma AB - Asset Resilience Ratio

Latest as of December 2025: 12.89%

Xbrane Biopharma AB (XBRANE) has an Asset Resilience Ratio of 12.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Xbrane Biopharma AB (XBRANE) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr86.59 Million

≈ $9.32 Million USD Cash + Short-term Investments

Total Assets

Skr671.62 Million

≈ $72.28 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2016)

This chart shows how Xbrane Biopharma AB's Asset Resilience Ratio has changed over time. See shareholders equity of Xbrane Biopharma AB for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Xbrane Biopharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see XBRANE company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr86.59 Million	12.89%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr86.59 Million	12.89%

Asset Resilience Insights

Moderate Liquidity: Xbrane Biopharma AB has 12.89% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Xbrane Biopharma AB Industry Peers by Asset Resilience Ratio

Compare Xbrane Biopharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Aktis Oncology, Inc. Common stock NASDAQ:AKTS	Biotechnology	23.64%
Janux Therapeutics Inc NASDAQ:JANX	Biotechnology	91.79%
Neurotech International Ltd AU:NTI	Biotechnology	0.22%
SynCore Biotechnology Co Ltd TWO:4192	Biotechnology	2.58%
Uniqure NV NASDAQ:QURE	Biotechnology	10.94%
Jazz Pharmaceuticals plc F:J7Z	Biotechnology	6.34%
Brainstorm Cell Therapeutics Inc NASDAQ:BCLI	Biotechnology	0.00%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%

Annual Asset Resilience Ratio for Xbrane Biopharma AB (2016–2016)

The table below shows the annual Asset Resilience Ratio data for Xbrane Biopharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2016-12-31	26.53%	Skr31.34 Million ≈ $3.37 Million	Skr118.11 Million ≈ $12.71 Million	--

pp = percentage points

About Xbrane Biopharma AB

ST:XBRANE Sweden Biotechnology

Market Cap

$24.39 Million

Skr226.66 Million SEK

Market Cap Rank

#24406 Global

#480 in Sweden

Share Price

Skr11.00

Change (1 day)

+10.00%

52-Week Range

Skr0.19 - Skr23.30

All Time High

Skr176.00